NCT03067610View on ClinicalTrials.gov

Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 20, 2017

Primary Completion Date

December 21, 2020

Study Completion Date

March 9, 2021

Conditions
Head and Neck CancerCarcinoma, Squamous CellNeoplasms, OralNeoplasms, Pharyngeal
Interventions
RADIATION

Intensity Modulated Radiation Therapy

The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.

DRUG

chemotherapy

chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion

Trial Locations (2)

60612

Rush University Medical Center, Chicago

75390

University of Texas Southwestern Medical Center - Dallas, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT03067610 - Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer | Biotech Hunter | Biotech Hunter